Invest Victoria recently profiled the strength of interactions between Cancer Trials Australia and BeiGene, a rapidly growing Chinese biopharmaceutical company, with over 1,700 staff across four continents and more than 40 clinical trials underway globally.

Since 2013 CTA has supported eight oncology clinical trials sponsored by BeiGene and conducted within Australian hospitals.

Xiaowei Shi, Executive Director of Clinical Operations in Asia-Pacific for BeiGene will co-present this successful partnership with CTA CEO Kurt Lackovic at the upcoming AusBiotech Asian Invest Series event in Shanghai on March 28.  The Invest Victoria profile can be found here